EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Heart Failure Pharmacotherapy

Dusty L Lisi, Kira Gaddis, Mahmoud H Abdou

Medical Clinics of North America · 2025

DOI: 10.1016/j.mcna.2025.04.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Clinics of North America, 2025. Verfasst von Dusty L Lisi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Emory St. Joseph's Hospital, Atlanta, GA, USA. Electronic address: dusty.lisi@emoryhealthcare.org. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacotherapy for heart failure (HF) with reduced ejection fraction (HFrEF) is the foundation of management. The basis of pharmacotherapy for HFrEF includes 4 pillars: beta-blockers, renin angiotensin aldosterone system modulators, mineralocorticoid receptor antagonists, and sodium glucose cotransporter 2 inhibitors. These drug classes collectively reduce mortality, hospitalizations, and can improve functional and clinical status. Additional pharmacotherapy with loop diuretics and sometimes addition of thiazide diuretics at the core can reduce HF symptoms. Contemporary data from recent randomized clinical trials have established a new foundation of successful management of patients with preserved ejection fraction HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureHumansMineralocorticoid Receptor AntagonistsAdrenergic beta-AntagonistsSodium-Glucose Transporter 2 InhibitorsStroke VolumeRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsSodium Potassium Chloride Symporter Inhibitors

Stichwörter der Autor:innen

Ejection fractionGDMTHeart failureHeart failure with preserved ejection fractionHeart failure with reduced ejection fraction

Substanzen

Mineralocorticoid Receptor AntagonistsAdrenergic beta-AntagonistsSodium-Glucose Transporter 2 InhibitorsAngiotensin-Converting Enzyme InhibitorsSodium Potassium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, Emory St. Joseph's Hospital, Atlanta, GA, USA. Electronic address: dusty.lisi@emoryhealthcare.org.
  • Department of Pharmacology, University of Mississippi School of Pharmacy, Jackson, MS, USA.
  • Department of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, USA.

Zitieren

APA

Lisi, D. L., Gaddis, K., & Abdou, M. H. (2025). Heart Failure Pharmacotherapy. Medical Clinics of North America. https://doi.org/10.1016/j.mcna.2025.04.003

Vancouver

Lisi DL, Gaddis K, Abdou MH. Heart Failure Pharmacotherapy. Medical Clinics of North America. 2025. doi:10.1016/j.mcna.2025.04.003

BibTeX
@article{Lisi2025,
  author = {Lisi, Dusty L and Gaddis, Kira and Abdou, Mahmoud H},
  title = {Heart Failure Pharmacotherapy},
  journal = {Medical Clinics of North America},
  year = {2025},
  doi = {10.1016/j.mcna.2025.04.003}
}
Kostenlos starten →